- Issue of patent vs public health
- India does not have enough production capacities which led to rise of second wave
- Compulsory licensing,even if its issued there is no necessary capability to develop same vaccine by other companies
- Data exclusivity: Even if vaccine waiver is provided but it does not lead to provision of research related information which can delay production of vaccine
- Reduces private investment and innovation in future in case of Vaccine waiver
- Lack of uniform vaccine pricing across all states causing Federal disputes
- Issue of vaccine hesitancy
- Vaccine diplomacy and scarcity of vaccines in India
Suggestions:
India should increase its production capabilities
Global pooling of resources and compensation of private players for innovation and improve vaccine availability to all nation
